E
FBIO icon

Ergoteles’s Fortress Biotech FBIO Stock Holding History

Ergoteles’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,904
Closed -$77.7K – 1408
2022
Q4 		$77.7K Sell
7,904
-6,685
-46% -$74K ﹤0.01% 1250
2022
Q3 		$188K Sell
14,589
-8,364
-36% -$125K 0.01% 1204
2022
Q2 		$289K Buy
+22,953
New +$340K 0.01% 1123

Other funds holding FBIO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $72.2B AUM 27.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ergoteles's FBIO Position: Q1 2023 in Review

Ergoteles sold out of Fortress Biotech (FBIO) in Q1 2023, closing a stake of 7,904 shares — an estimated $77.7K sold.

Ergoteles first reported a position in FBIO in Q2 2022 and held it in 3 quarters. The position peaked at $289K in Q2 2022. 54 funds tracked by Wall St. Rank hold FBIO as of Q1 2023.

  • Ergoteles reported no remaining Fortress Biotech position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 7,904 Fortress Biotech shares in Q1 2023, an estimated $77.7K.
  • Ergoteles first reported a position in Fortress Biotech in Q2 2022 and held it in 3 quarters.
  • Ergoteles's Fortress Biotech position peaked at $289K in Q2 2022.
  • 54 funds tracked by Wall St. Rank held Fortress Biotech as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.